Howard Quint, MD
Pain Medicine · Edmonds, WANPI 1497984850
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,274 and has fallen 96.3% since, to $47 in 2024.
Across 175 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$608
- Lilly USA, LLC$252
- Pfizer$248
- Amgen$230
- Supernus Pharmaceuticals, Inc.$180
- Biohaven Pharmaceuticals, Inc.$175
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,04399%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 40 | $608 |
| Lilly USA, LLC | 14 | $252 |
| Pfizer | 10 | $248 |
| Amgen(2 entities) | 12 | $230 |
| Supernus Pharmaceuticals, Inc. | 13 | $180 |
| Biohaven Pharmaceuticals, Inc. | 8 | $175 |
| Zyla Life Sciences, Inc. | 11 | $164 |
| Scilex Pharmaceuticals Inc. | 7 | $141 |
| Sentynl Therapeutics, Inc. | 11 | $139 |
| Arbor Pharmaceuticals, Inc. | 7 | $121 |
| Teva Pharmaceuticals USA, Inc. | 4 | $119 |
| Assertio Therapeutics, Inc. | 7 | $116 |
| AbbVie | 3 | $66 |
| Vertical Pharmaceuticals, LLC | 4 | $61 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Novartis | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $50 |
| Virtus Pharmaceuticals LLC | 2 | $47 |
| Kaleo, Inc. | 3 | $47 |
| Indivior Inc. | 2 | $38 |
| Orexo US, Inc. | 2 | $31 |
| Stimwave Technologies Incorporated | 1 | $25 |
| Biodelivery Sciences International, Inc. | 2 | $24 |
| GRT US Holding, Inc. | 1 | $23 |
| Gilead | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Neuronetics, Inc. | 1 | $13 |
How this compares
$3,070 in reported general payments places this provider in the 60th percentile of 124 pain medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 1,809 | $52,804 |
| OxycontinOxycodone Hcl | 60 | $39,180 |
| Methadone Hcl | 528 | $16,435 |
| Morphine Sulfate ErMorphine Sulfate | 615 | $16,076 |
| Fentanyl | 80 | $13,850 |
| Xtampza ErOxycodone Myristate | 23 | $12,266 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 156 | $7,724 |
| LinzessLinaclotide | 13 | $7,360 |
| Hydromorphone Hcl | 115 | $5,775 |
| Morphine Sulfate | 120 | $5,625 |
| Gabapentin | 394 | $5,392 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $3,773 |
| Tizanidine Hcl | 436 | $3,191 |
| Lidocaine | 20 | $1,953 |
| Buprenorphine Hcl | 67 | $1,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $608 | $12,26623 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate, Buprenorphine-Naloxone, Buprenorphine Hcl | $21 | $11,148213 claims |
| AbbVieLinzess | $66 | $7,36013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 124 pain medicine providers in Washington.
Other pain medicine in Edmonds
- Praveen MambalamEdmonds$32K
- Rajninder JutlaEdmonds$5K
- Jennifer LeeKirkland$318K
- Steven StanosSeattle$206K
- Corrie AndersonSeattle$102K
- Gregory TermanSeattle$95K
- Caroline HarstroemEverett$74K
- Sloane YuVancouver$42K
- Miroslav BackonjaSeattle$22K
- Ross VogelgesangOlympia$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.